Amiodarone-induced pulmonary toxicity (APT) is a serious adverse event that can lead to death. The aims of our study are to determine factors associated with mortality and to describe outcome and sequelae of patients with APT. Methods: Forty-six patients with APT were divided into two groups according to survival at day 90 for a clinical, functional, biological and radiological comparaison. We then evaluated the evolution of 15 survivors at a median of three months [1e6 months] and/or 12 months [8 e36 months]. Results: Mortality of APT at day 90 was 37% (17 patients) and was linked to the speed of onset of symptoms and a high HRCT alveolar score. Angiotensin system antagonist treatment was prescribed significantly more in the survival group (p Z 0.042, HR 0.34 (95% CI 0.12e0.96)). In surviving patients, dyspnea, vital capacity and HRCT alveolar score improved significantly while HRCT fibrosis score deteriorated gradually during the first six months. At the end of the study, all the surviving patients presented functional and/or radiological sequelae.
Conclusions: Severity of APT is linked to the extent and speed of onset of pulmonary damage. After the initial episode, the patients who survived improved slowly but with persistent sequelae. ª 2014 Elsevier Ltd. All rights reserved.
Amiodarone is one of the most commonly prescribed antiarrhythmic drugs and is considered the most effective. Amiodarone-induced pulmonary toxicity (APT) occurs in 0.1e17% [1] of cases, with mortality ranging from 1 to 50% when Acute Respiratory Distress Syndrome (ARDS) develops [2e4] . Several mechanisms have been proposed to explain this toxicity [2,5e9] : direct drug-induced phospholipidosis secondary to lysosomal phospholipase inhibition and phospholipid accumulation due to the amphiphilic properties of amiodarone's metabolite, N-desethylamiodarone (DEA). DEA concentrates in organs with high lipid content, such as adipose tissue, the thyroid, liver and lungs. The clinical manifestation of phospholipidosis is the presence of foamy cells in bronchoalveolar lavage (BAL). However, foamy cells are not specific for amiodarone pulmonary toxicity and are currently considered merely to reflect the effect of a drug. An immunological hypothesis can also be put forward, based on the observation of T-cell infiltrates in some patients [7,10e12] .
A dose-dependent effect was initially described, and high cumulative dose, high daily dosage (>400 mg/d) and duration of therapy (>12 months) are commonly recognized risk factors for pulmonary toxicity. However, some recent publications have reported toxicity with lower amiodarone doses or after only a few weeks of amiodarone therapy [13e16] . Many other risk factors have been described for amiodarone lung toxicity, notably age, but also male gender, pre-existing lung disease, renal disease, surgery, and high concentrations of inspired oxygen [3,17e24] . Clinical practice suggests that the outcome of APT after the initial episode is favorable after discontinuation of amiodarone, with or without corticosteroids [25] .
To our knowledge, no study has evaluated the factors associated with mortality and pulmonary sequelae of APT. The aims of our retrospective study in patients with APT were to determine factors associated with mortality and to describe the medium-and long-term clinical, physiological and radiological pulmonary outcomes.
Methods

Patients
Our study was retrospectively conducted in the respiratory medicine department and intensive care unit of the university hospital of Tours, France. We reviewed 101 cases of drug-induced pulmonary toxicity among patients hospitalized between January 2000 and August 2011 ( Fig. 1 ). Fiftyfive patients were excluded, 43 because they had not received amiodarone during the previous month and 12 because of insufficient data to establish the diagnosis of APT.
French legislation does not require the agreement of an ethics committee, nor the informed consent of patients, for the retrospective collection of data that conform to current practice. However, the study protocol was evaluated and approved by the Institutional review board of the French Society for Respiratory Medicine (Société de Pneumologie de Langue Française) (CEPRO 2011-031). The database was anonymous and complied with the restrictive requirements of the Commission Nationale de l'Informatique et des Libertés, the organization that ensures the application of data privacy laws in France.
Forty-six patients were diagnosed as having APT based on intrinsic and extrinsic pharmacological imputability criteria. The diagnosis criteria of APT were: a/amiodarone treatment at the time of diagnosis, b/new or worsening respiratory symptoms, c/new pulmonary infiltrates on chest radiography or high-resolution computed tomography (HRCT), d/exclusion of differential alternatives (cardiogenic edema, sepsis, other drug-induced pulmonary diseases), and e/improvement shown by surviving patients after amiodarone withdrawal, with or without corticosteroids.
Initial investigations
We collected the following data from the medical file of each patient: age, sex, body mass index (BMI), duration of therapy, cumulative dose, angiotensin system antagonist (ASA) treatment, time between onset of symptoms and hospitalization and between hospitalization and APT diagnosis, clinical data (cough, dyspnea, .), biological data (PaO2/FiO2 rate, BAL,...), ICU admission, treatment modalities (mechanical ventilation, steroids) and pulmonary function test (PFT, see method in the Online Data Supplement).
All patients underwent HRCT of the lung at baseline. Ground-glass opacities and alveolar consolidations were quantified to give an active lesion score (or HRCT alveolar score), while traction bronchiectasis, scissural distortions and honeycombing were considered to represent fibrotic lesions and were quantified to produce an HRCT fibrosis score (see method in the Online Data Supplement).
Patient follow-up after initial hospitalization
For 15 of the 29 surviving patients we compared clinical (dyspnea), physiological and radiological data at medium term (median 3 months, range 1e6 months, after APT diagnosis) and/or long term (median 12 months, range 8e36 months, after APT diagnosis) with initial data. The other 14 surviving patients were lost or data were insufficient. The clinical features of lost patients did not differ from those of followed-up patients, except that they were older (e- Table 1 in Online Data Supplement). Among 15 followed patients, there was no difference in clinical, functional and radiological characteristics in the long term between older and younger patients (data not shown).
Statistical analysis
A non-parametric method was used, and all data are expressed as median [range] values. The Mann Whitney test was performed to compare survival and non-survival groups. Chi-Squared and Fischer tests were used to compare category data for each group. Survival curves were constructed using the KaplaneMeier method with a statistical comparison based on the log-rank test. The Wilcoxon signed-rank test was performed to evaluate the significance of clinical, physiological and radiological changes between baseline and follow-up. The correlations were assessed with the Spearman's rank-order test. Statistical significance was defined as a p-value of <0.05. 
Results
Baseline characteristics
Clinical data (Table 1) We selected 46 patients with diagnostic criteria for APT based on intrinsic and extrinsic pharmacological imputability. Amiodarone had been prescribed in 45 patients for atrial fibrillation and in one patient for ventricular arrhythmia. Patients were divided into two groups according to survival at 90 days. For the seventeen patients in the non-survival group (37%), median time of death was the seventeenth day of hospitalization [3e65 days after admission]; Ten died of amiodarone-induced ARDS, 6 patients died of multiple organ failure (one septic shock, one exacerbation of cirrhosis, four patients with multiple comorbidities after opting for palliative care), 1 patient died of herpetic meningitis after corticotherapy. The cumulative dose and duration of amiodarone therapy did not differ significantly between the two groups, nor age, sex ratio, BMI, pulmonary or cardiac co-morbidities. Angiotensin system antagonist (ASA) treatment had been prescribed significantly more in the survival group (p Z 0.042, HR 0.34 (95% CI 0.12e0.96)) ( Fig. 2) . Clinical features did not differ between the two groups (fever, asthenia, chest pain, cough, sputum, hemoptysis), except that symptoms occurred earlier (3 weeks [1, 21] versus 7 weeks [3; 42], p Z 0.003) and dyspnea was more severe (p Z 0.007) in the non-survival group.
Biological findings (Table 1) Apart from a lower PaO2/FiO2 ratio in the non-survival group (p Z 0.024), no other biological data were predictive of mortality. There was no significant difference in BAL bacterial culture or cell fraction (n Z 28, e- Table 2 in Online Data Supplement). HRCT (Table 2) HRCT was performed in 22 patients (76%) in the survival group and 13 patients (76%) in the non-survival group, at a median of 3e5 days following admission. In all patients we found diffuse and bilateral ground-glass opacities with Table 2 HRCT characteristics of surviving and non-surviving patients with amiodarone pulmonary toxicity. Ground-glass opacities and alveolar consolidations were quantified to give an active lesion score (or HRCT alveolar score), while traction bronchiectasis, scissural distortions and honeycombing were considered to represent fibrotic lesions and were quantified to produce an HRCT fibrosis score. Six areas of the lung were defined: the upper, middle and lower zones. Opacity intensity on thin section HRCT was scored semi-quantitatively: 1 Z less than 25% of total lung parenchyma in the area, 2 Z 25e50%, 3 Z 50e75%, 4 Z more than 75%, yielding a total score (total: 0e24). alveolar consolidation (Fig. 4a ). The HRCT alveolar score was significantly higher in the non-survival than the survival group (20 [17, 23] versus 18 [8, 23] , p Z 0.004), with more homogeneous distribution (p Z 0.004). PaO2/FiO2 ratio was inversely correlated with the HRCT alveolar score (Rho Z À0.692, p Z 0.001). The other abnormalities (fibrotic lesions, lymphadenopathies, pleural effusion, lobular attenuation, reticulation) did not differ significantly between the two groups.
Pulmonary function tests
Initial treatment
There were no differences concerning ICU admission and mechanical ventilation. The APT diagnosis was made at a median of three days post-admission. After diagnosis, amiodarone was stopped. Corticosteroids were administered to 83% of the patients at a median dose of 1 mg/kg [0.5e5 mg/kg] with no difference between the two groups.
Follow-up
Clinical and physiological data We followed up 15 surviving patients. Amiodarone was withdrawn in all cases and 60% of patients were given corticosteroids for an initial duration of 3e29 months. The three patients treated for less than three months relapsed and corticosteroid treatment was renewed. No relapse was observed among patients treated for more than six months. After initial diagnosis of APT, clinical, physiological and HRCT assessments were carried out at medium term (median 3 months, range 1e6 months, after APT diagnosis) and/or long term (median 12 months, range 8e36 months, after APT diagnosis). In all 15 cases, cough, fever and asthenia disappeared during the first six months (at medium term). Dyspnea partially improved, with median MMRC (Modified Medical Research Council) dyspnea scale decreasing from 4 to 2 (p Z 0.008). At long term, all but two patients were at their previous level of dyspnea (no dyspnea in three cases) ( Table  3 and Fig. 3 ).
VC improved significantly at medium term and at long term. TLC and DLCO improved, but not significantly. At the end of the study, five patients had a persistent restrictive syndrome. PaO2/FiO2 ratio significantly improved in the first few months (at medium term), increasing from 238 mmHg to 419 mmHg (Fig. 3 ). PaO2 was not evaluated after four months of APT diagnosis.
HRCT data (Table 4 ) An improvement in alveolar opacities was observed at medium term, with HRCT alveolar score decreasing by more than 40% (p Z 0.05), and continued at long term without normalization. Fibrotic lesions were observed at APT diagnosis in 10 of the 15 patients, with a progressive and moderate, but significant (p < 0.05), increase mainly at medium term. Lesions consisted mainly of traction bronchiectasis and scissural distortions. We found honeycombing lesions (not suggestive of the usual interstitial pneumonia pattern) in only one case in whom no other lung fibrosis etiology was found. The other initial abnormalities (reticulation, lobular attenuation, pleural effusion and adenopathy) improved. None of the patients had normalized their CT-scan at long term. Fig. 3a ) and functional improvement (Fig. 3b, c, d) between the initial assessment, the medium-term (1e6 months) and long-term evaluation (8e36 months). Closed circles: patients with corticotherapy. Open circles: patients without corticotherapy. Individual values and median (bar). *p < 0.05 medium-term versus initial scores, yp < 0.05 long-term versus medium-term scores, $ p < 0.05 long-term versus initial scores.
Corticosteroid effect
Nine of the 15 patients (60%) received corticosteroid therapy and amiodarone was stopped in all cases. Treatedpatients had a more severe APT (PaO2/FiO2 and alveolitis score) with greater improvement of their MMRC score (p Z 0.007) and VC (p Z 0.02) than non-treated patients at long term, but there was no difference in HRCT evolution.
Discussion
In our study, 17 patients (37%) with APT died during hospitalization. The rapid onset of the clinical picture, the initial severity (PaO2/FiO2), the extent of lung injury on HRCT, and the homogeneous distribution were poor prognostic factors. Conversely, ASA treatment appeared as a potentially protective factor. Furthermore, all the patients who initially survived APT showed clinical, functional and radiological improvement when amiodarone was withdrawn, with or without corticosteroids. This improvement was slow and extended beyond six months after initial support. However, physiological and/or radiological sequelae were observed in all patients.
There is no clinical, physiological, biological or radiological gold standard to diagnose APT. In our patients, a diagnosis of APT was made based on intrinsic and extrinsic Figure 4 Representative HRCT scan of amiodarone-induced pneumonia in an 88-year-old patient at diagnosis (Fig. 4a ) and 10.5 months after discontinuation of amiodarone with 6 months of corticosteroid therapy (Fig. 4b ). HRCT alveolar (Fig. 4c ) and fibrosis (Fig. 4d ) score improvements between initial assessment, medium-term (1e6 months) and long-term (8e36 months) evaluation. Closed circles: patients with corticotherapy. Open circles: patients without corticotherapy. Individual values and median (bar). *p < 0.05 medium-term versus initial scores, yp < 0.05 long-term versus medium-term scores, $ p < 0.05 long-term versus initial scores. There are several clinical presentations of APT: a chronic form, indolent with few or no symptoms, a sub-acute form which is the most common, and rarely ARDS. Our patients mainly presented sub-acute forms. Seventeen patients died during their hospitalization (37%) including 9 from amiodarone-induced ARDS, which is consistent with previously reported series [2] . Age and amiodarone exposure (cumulative dose, daily dosage, and long-term therapy) are the most widely published risk factors of amiodarone toxicity [3,17e24] . No previous study has determined prognosis factors. In our study, we found shorter clinical onset and more severe hypoxemia in non-surviving patients. This has been observed in cardiac surgery with the use of intravenous amiodarone for the prevention of perioperative arrhythmia [2, 18] . This observation could support the hypothesis of an allergic immune reaction against amiodarone or its metabolites during severe APT. We observed that patients treated with inhibitors of the renin-angiotensin system had a lower risk of mortality. Some authors have reported that these agents have a protective effect against APT [26] . In vitro, apoptosis of alveolar epithelial cells induced by amiodarone increases in the presence of angiotensin II and is reduced by renin-angiotensin system antagonists [26] .
Many authors have studied the initial radiological manifestations of APT [21,27e35] . The lesions are mainly nonspecific, with an alveolar syndrome involving ground-glass opacities and alveolar consolidation. In our patients, the extent of alveolar opacities was greater in the non-survival group and was the only radiological criterion correlating closely with the PaO2/FiO2 ratio and mortality. A correlation between HRCT involvement and severity scores, including PaO2/FiO2 ratio [36] and mortality [37, 38] in infectious and non-infectious ARDS, has previously been reported. Other commonly observed opacities, such as intralobular reticulations, thickening of the interlobular septa, pleural effusions and signs of pulmonary fibrosis (honeycombing and traction bronchiectasis) were found in our study, but they were not prognostic factors.
To our knowledge, our study is the first to report in a semi-quantitative way the clinical, physiological and radiological evolution of patients with APT. The improvement of symptoms following withdrawal of amiodarone has previously been described [25, 31, 35] . The respiratory symptoms of our patients returned to normal at medium term (1e6 months), except for dyspnea which continued to improve between the second and third evaluation (at 1e3 months and 8e36 months respectively). At long term (8_ to 36 months), the dyspnea score of all but two patients returned to their pre-APT score. The slow improvement of the respiratory status of our patients is also reflected in the physiological data, with a slight but significant improvement of VC, TLC and DLCO after 8e36 months.
In our study, ground-glass opacities, consolidation, intraalveolar reticulations and pleural effusions improved after withdrawal of amiodarone. Only a few case reports [31, 34] and one study [35] have examined HRCT evolution of APT after amiodarone withdrawal. Vernhet et al. observed a normalization of chest X-rays in 16 out of 20 patients. Only one of the four patients who had an HRCT evaluation at three months no longer had pulmonary opacities. However, there is no information regarding the severity of APT.
After 8e36 months, patients retained a respiratory disability characterized by dyspnea and a decrease in DLCO (in 12 out of 15 patients). Residual radiological ground-glass opacities, intralobular reticulations and signs of pulmonary fibrosis observed at the third evaluation were localized mainly in the initially most affected areas. Fibrosis score was the only radiological parameter that worsened over time, mainly in the first six months following withdrawal of amiodarone.
Treatment with systemic corticosteroids was initiated in 60% of surviving patients (9/15) for a period of 3e29 months. Corticosteroids are currently recommended for 6e12 months in patients with the most severe presentation or who show no improvement after stopping amiodarone, with no evidence of any impact on mortality [9, 25] . In our study, corticosteroids were initiated in more severe cases and had a positive effect on alveolar opacities observed at APT diagnosis. Moreover, despite Table 4 HRCT characteristics between initial assessment, mid-term (1e6 months) and long-term evaluation (8e36 months). Ground-glass opacities and alveolar consolidations were quantified to give an active lesion score (or HRCT alveolar score), while traction bronchiectasis, scissural distortions and honeycombing were considered to represent fibrotic lesions and were quantified to produce an HRCT fibrosis score Six areas of the lung were defined: the upper, middle and lower zones. Opacity intensity on thin section HRCT was scored semi-quantitatively: 1 Z less than 25% of total lung parenchyma in the area, 2 Z 25e50%, 3 Z 50e75%, 4 Z more than 75%, yielding a total score (total: 0e24 corticosteroid therapy, the fibrosis score of some patients increased at medium term (1e6 months). APT relapse was observed when treatment lasted less than three months but not when it lasted longer than six months. The long half-life elimination of amiodarone (40e70 days) and its storage in lung parenchyma probably explain the slow improvement in APT and relapse within three months of corticosteroid therapy [7] . This study has some limitations. First, because of its retrospective nature, nearly half of the surviving patients were lost, limiting the conclusions. Lost patients were older, but there were no other baseline differences with followed-up patients. They were probably lost because of their age and the absence of the expected benefits of repeated HRCT or functional tests. Among the 15 followedup patients, there were no long-term differences in clinical, functional and radiological characteristics between older and younger patients. There was also a selection bias in that our study only included hospitalized patients, who were probably more severe cases with higher mortality rates than out-patients. Finally the main limitation is the small sample size and a prospective study will be necessary to confirm our observation.
APT mortality may be related to rapid onset and the extent of lung injury. In patients who are treated for APT, improvement is slow and extends beyond six months after discontinuation of amiodarone, with or without systemic corticosteroids. All patients presented functional and/or radiological sequelae at 12 months. Further studies are needed to evaluate the benefit of oral corticosteroids following APT.
